This study checks if a drug called Zunveyl® is safe and comfortable for people with Alzheimer's disease (AD), a brain disorder affecting memory and thinking. It lasts for 12 weeks and involves adults aged 50 and above with mild to moderate AD. People in the study will be tested using the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test to confirm AD. They must have a caregiver who can help with the study.

Some people cannot join this study, like those with other types of dementia or mental health issues or if they have certain medical conditions. Participants cannot have used Zunveyl® before or be on conflicting medications. They also need to be stable on their current medications for at least 4 weeks before starting the study.

• The study lasts 12 weeks and involves several visits.
• A caregiver must be available for the entire study.
• Participants must be over 50 years old and confirmed to have mild to moderate AD.